|
|
|
|
|
|
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项在局部晚期或转移性实体瘤患者中评价PTT-936(一种α激酶1[ALPK1]激动剂)单药治疗或与PD-1/L1抗体联合治疗的安全性、药代动力学和有效性的I/IIa期研究
[Translation] A Phase I/IIa Study Evaluating the Safety, Pharmacokinetics, and Efficacy of PTT-936 (an Alpha Kinase 1 [ALPK1] Agonist) as Monotherapy or in Combination with a PD-1/L1 Antibody in Patients with Locally Advanced or Metastatic Solid Tumors
主要目的:评价在药理学活性剂量(PAD)范围内使用PTT-936单药治疗SOC后病情进展或无SOC的晚期不可切除或转移性实体瘤患者的安全性和耐受性,其中可能包括确定MTD
[Translation] Primary Objective: To evaluate the safety and tolerability of PTT-936 monotherapy in patients with advanced unresectable or metastatic solid tumors who have progressed on SOC or who do not have SOC within the pharmacologically active dose (PAD) range, which may include determining the MTD
A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination With Anti-PD-1/L1 in Patients With Locally Advanced or Metastatic Solid Tumors
This Phase 1/2a study will explore the safety and efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) activator, used alone or in combination with anti-PD-1/L1 therapy in patients with locally advanced or metastatic solid tumors. The study is divided into two parts: Phase 1 (Part A) focuses on determining the pharmaceutically active dosage range and evaluating the safety profile of PTT-936 when administered as a monotherapy. Phase 2a (Part B) will assess the safety and efficacy of PTT-936 combined with anti-PD-1/L1 therapy in patients suitable for anti- PD-1/L1 monotherapy. The study aims to understand how PTT-936, alone or in combination, impacts tumor progression and patients' overall response.
100 Clinical Results associated with Pyrotech Therapeutics, Inc.
0 Patents (Medical) associated with Pyrotech Therapeutics, Inc.
100 Deals associated with Pyrotech Therapeutics, Inc.
100 Translational Medicine associated with Pyrotech Therapeutics, Inc.